论文信息 - LBA35 Phase II study of PARP inhibitor talazoparib and PD-L1 inhibitor avelumab in patients (pts) with microsatellite stable (MSS) recurrent/persistent endometrial cancer - 字舞流文

LBA35 Phase II study of PARP inhibitor talazoparib and PD-L1 inhibitor avelumab in patients (pts) with microsatellite stable (MSS) recurrent/persistent endometrial cancer

Cesar M. Castro | S. Cannistra | U. Matulonis | G. Fleming | P. Konstantinopoulos | N. Xiong | Joyce F. Liu | R. Penson | M. Buss | N. Tayob | C. Krasner | S. Campos | A. Gockley | M. Shea | S. Schumer | S. Bouberhan | C. Whalen | A. Wright | M. Polak | Y. Oladapo